FIELD: pharmaceuticals.
SUBSTANCE: invention relates to novel cyclic dinucleotide derivatives (CDNs) with STING agonist activity, antibody-drug conjugates formed by conjugating novel cyclic dinucleotide derivatives and antibodies against target cells to each other via a linker, a pharmaceutical composition containing antibody-drug conjugates, and a method of treating cancer associated with STING agonist activity.
EFFECT: obtaining a new cyclic dinucleotide derivative and its antibody-drug conjugate.
82 cl, 22 dwg, 2 tbl, 127 ex
| Title | Year | Author | Number |
|---|---|---|---|
| LIGAND-DRUG CONJUGATE OF EXATECAN ANALOGUE, ITS PRODUCTION METHOD AND ITS USE | 2019 |
|
RU2793316C2 |
| CONJUGATE ANTIBODY-DERIVATIVE OF PYRROLOBENZODIAZEPINE | 2018 |
|
RU2820928C2 |
| AZALACTAM COMPOUNDS AS INHIBITORS OF HPK1 | 2021 |
|
RU2819642C1 |
| DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS SUITABLE AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | 2018 |
|
RU2804468C2 |
| SULFOMALEIMIDE-BASED LINKERS AND CORRESPONDING CONJUGATES | 2019 |
|
RU2815199C2 |
| ANTIBODY AND DRUG CONJUGATES (ADC) AND ANTIBODY AND PRODRUG CONJUGATES (APDC) CONTAINING ENZYMATICALLY CLEAVABLE GROUPS | 2016 |
|
RU2751512C2 |
| ANTIBODY TO B7H3-EXATECAN ANALOGUE CONJUGATE AND ITS USE IN MEDICINE | 2019 |
|
RU2785664C2 |
| N1/N2-LACTAM ACETYL-CoA-CARBOXYLASE INHIBITORS | 2011 |
|
RU2540337C2 |
| ANTI-BCMA ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND MEDICAL USE THEREOF | 2020 |
|
RU2819660C2 |
| ANTI-HER2 ANTIBODY DRUG CONJUGATE | 2015 |
|
RU2794183C2 |
